EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
Makoto Nishio(Japanese Foundation For Cancer Research), Tomohide Tamura(St. Luke's International Hospital), Toshiaki Takahashi(Okayama University), Hiroshi Nokihara(Tokushima University Hospital), L. Zhang(Sun Yat-sen University), Ross A. Soo(National University Cancer Institute, Singapore), Nobuyuki Yamamoto(Wakayama Medical University), Wan‐Teck Lim(National Cancer Centre Singapore), Kōichi Goto(National Cancer Center Hospital East), James Chih‐Hsin Yang(National Taiwan University Hospital), Ying Cheng(Jilin Province Tumor Hospital), Tony Mok(Chinese University of Hong Kong), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Y. Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Satoshi Morita(Kyoto University), J. Chang(Fudan University Shanghai Cancer Center), Shun Lü(Shanghai Jiao Tong University), Y. Ichinose, Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 10
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k